8-K: Ionis Partner GSK Reports Positive Phase 3 Bepirovirsen Results

Ionis Pharmaceuticals' partner GSK announced positive topline results from two pivotal Phase 3 studies for bepirovirsen, an investigational treatment for chronic hepatitis B, demonstrating a statistically significant functional cure rate.

Summary

• GSK, Ionis' partner, reported positive results from two pivotal Phase 3 studies, B-Well 1 and B-Well 2, evaluating bepirovirsen for chronic hepatitis B (CHB).
• The studies included over 1,800 patients from 29 countries.
• The B-Well studies met their primary endpoint, demonstrating a statistically significant and clinically meaningful functional cure rate.
• Functional cure rates were significantly higher with bepirovirsen plus standard of care compared with standard of care alone.
• Results were statistically significant across all ranked endpoints, with an even greater effect in patients with baseline surface antigen (HBsAg) <=1000 IU/ml.
• Bepirovirsen demonstrated an acceptable safety and tolerability profile consistent with previous studies.
• CHB affects over 250 million people worldwide and is the leading cause of liver cancer, with current standard of care offering low functional cure rates (typically 1%).
• If approved, bepirovirsen has the potential to be the first finite, six-month therapeutic option for CHB and a backbone for future treatment strategies.
• Bepirovirsen has received Fast Track designation from the US FDA, Breakthrough Therapy designation in China, and SENKU designation in Japan.
• Under the 2019 licensing agreement with GSK, Ionis is eligible to receive an additional $150 million in regulatory and sales milestone payments, plus tiered royalties of 10-12% on net sales.

Sentiment

Score: 9

Explanation: The announcement of positive Phase 3 results for bepirovirsen, a potential first-in-class treatment for a widespread and serious disease like chronic hepatitis B, is highly positive. The drug demonstrated statistically significant and clinically meaningful functional cure rates with an acceptable safety profile, addressing a significant unmet medical need. The financial terms for Ionis, including substantial milestone payments and tiered royalties, further enhance the positive sentiment.

Positives

• Positive topline results from two pivotal Phase 3 studies (B-Well 1 and B-Well 2) for bepirovirsen.
• Studies met their primary endpoint, demonstrating a statistically significant and clinically meaningful functional cure rate for chronic hepatitis B.
• Bepirovirsen showed an acceptable safety and tolerability profile.
• Potential to be the first finite, six-month therapeutic option for chronic hepatitis B, addressing a significant unmet medical need.
• Received multiple regulatory designations: Fast Track (US FDA), Breakthrough Therapy (China), and SENKU (Japan).
• Ionis is eligible for an additional $150 million in regulatory and sales milestone payments from GSK.
• Ionis will receive tiered royalties of 10-12% on net sales of bepirovirsen.
• This is the first of five anticipated Phase 3 readouts from Ionis' partnered programs this year.

Risks

• Actual events or results may differ materially from expectations due to inherent risks and uncertainties in discovering, developing, and commercializing safe and effective human therapeutics.
• Risks associated with building a business around such medicines.
• Forward-looking statements involve assumptions that, if they never materialize or prove correct, could cause results to differ materially.
• Additional factors that could cause actual results to differ materially are disclosed in Ionis' SEC filings, including the Risk Factors section in its most recent Annual Report on Form 10-K and subsequently filed Quarterly Reports on Form 10-Q.

Future Outlook

Global regulatory submissions for bepirovirsen are planned from Q1 2026. If approved, bepirovirsen has the potential to become the first finite, six-month therapeutic option for chronic hepatitis B and to serve as a backbone for future sequential treatment strategies. Ionis anticipates five Phase 3 readouts from its partnered programs this year, underscoring the broad applicability of its technology.

Management Comments

• "Bepirovirsen is uniquely positioned to effectively treat CHB based on its potential to reduce the replication of hepatitis B virus, suppress hepatitis B surface antigen and stimulate the immune system." Brett P. Monia, Ph.D., chief executive officer, Ionis.
• "Today's positive results are made possible by the strategic collaboration between Ionis and GSK, and demonstrate that bepirovirsen has the potential to bring hope to the millions of people living with CHB." Brett P. Monia, Ph.D., chief executive officer, Ionis.
• "This is the first of five anticipated Phase 3 readouts from Ionis partnered programs this year, underscoring the broad applicability of our technology." Brett P. Monia, Ph.D., chief executive officer, Ionis.

Industry Context

Chronic hepatitis B (CHB) is a major global health challenge, affecting over 250 million people worldwide and causing approximately 1.1 million deaths annually, accounting for about 56% of liver cancer cases. The current standard of care, nucleos(t)ide analogues, often requires lifelong therapy and achieves low functional cure rates, typically only 1%. Bepirovirsen's potential as a finite, six-month therapeutic option with a statistically significant and clinically meaningful functional cure rate represents a significant advancement that could transform CHB treatment and address a critical unmet medical need.

Comparison to Industry Standards

• Current standard of care for chronic hepatitis B (nucleos(t)ide analogues) typically achieves functional cure rates of only 1% and often requires lifelong therapy.
• Bepirovirsen demonstrated a statistically significant and clinically meaningful functional cure rate, which is a substantial improvement over the existing 1% benchmark.
• The potential for bepirovirsen to be a finite, six-month therapeutic option contrasts sharply with the lifelong therapy often required by current treatments, offering a significant advantage in patient management and quality of life.

Stakeholder Impact

• Shareholders: Positive impact due to significant de-risking of a key pipeline asset, potential for substantial future revenue from milestone payments and royalties, and enhanced market position.
• Patients with Chronic Hepatitis B: Highly positive impact due to the potential availability of a first-in-class, finite, and more effective treatment option that could lead to functional cure and reduce long-term liver complications.
• Healthcare Providers: Positive impact by gaining a new, potentially superior therapeutic option for managing chronic hepatitis B, offering better outcomes for patients.

Next Steps

• Full results will be submitted for presentation at an upcoming scientific congress.
• Full results will be published in a peer-reviewed journal.
• Full results will be used to support regulatory submissions to health authorities worldwide, planned from Q1 2026.

Key Dates

Recommendation

The positive Phase 3 results for bepirovirsen represent a significant de-risking event for Ionis, validating its RNA-targeted medicine platform for a major global health challenge. The drug's potential as a first-in-class, finite treatment for chronic hepatitis B, a disease affecting over 250 million people with limited effective long-term options, positions it for substantial market penetration. The financial terms with GSK, including significant milestone payments and tiered royalties, promise considerable future revenue streams for Ionis. This clinical success, coupled with the large market opportunity and the potential to revolutionize CHB treatment, makes Ionis a strong buy for investors seeking exposure to innovative biotechnology with clear commercialization pathways.

Keywords

Hepatitis B, CHB, bepirovirsen, Phase 3, clinical trial, functional cure, GSK, Ionis Pharmaceuticals, ASO, antisense oligonucleotide, liver cancer, antiviral, drug development, regulatory approval